Hakan Sarbay

Hakan Sarbay

Auto-generated profile, based on publicly available information

Hakan Sarbay

Department of Pediatric Hematology and Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
YBYasemin Isik Balci
Yasemin Isik Balci
SASemra Acer
Semra Acer
RYRamazan Yagci
Ramazan Yagci
VKVural Kucukatay
Vural Kucukatay
HSHakan Sarbay
Hakan Sarbay
APAziz Polat
Aziz Polat

6 October 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
HSHakan Sarbay
Hakan Sarbay
ÜDÜlkü F. Demir
Ülkü F. Demir
GYGüliz Yılmaz
Güliz Yılmaz
AAAbdullah A. Atay
Abdullah A. Atay
BMBarış Malbora
Barış Malbora
Background: Ifosfamide (IFO) is an alkylating agent used to treat broad range of malignancies. One of the life-threatening toxic effects is reversible neurotoxicity. In this report; we presented a case report of ifosfamide induced encephalopathy (IIE) in a child with osteosarcoma in order to emphize that it is important to continue ifosfamide treatment as well as the importance of this potentially fatal complication. Case report: Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings. Laboratory analyzes before and after ifosfamide infusion were normal. No pathological findings were seen on MR imaging. Hypoglycemia, electrolyte disturbances, encephalitis, meningitis, metastasis and posterior reversible encephalopathy syndrome (PRES) were not considered. Electroencephalography was found compatible with neuronal hyperexcitability originating from the left hemisphere. With the diagnosis of ifosfamide induced encephalopathy, prophylaxis with methylene blue was received before the next infusion of ifosfamide. Neurological findings were not observed in the patient's follow-up. Conclusion: Patients who develop IIE can continue their treatment protocol with methylene blue prophylaxis and supportive therapy.

6 May 2021 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
HSHakan Sarbay
Hakan Sarbay
SHSamira Hagverdiyeva
Samira Hagverdiyeva
ETEmine Turkkan
Emine Turkkan
SASeyhmus Akcay
Seyhmus Akcay
AAAvni Atay
Avni Atay
BMBaris Malbora
Baris Malbora

1 January 2019 in Pan African Medical Journal
Verified
Journal Article
Open access
HSHakan Sarbay
Hakan Sarbay
SASinan Akbayram
Sinan Akbayram
Thrombocytosis is a frequently seen condition during childhood. While it usually develops secondarily due to reasons such as infection or anemia, it may rarely develop due to clonal causes. Thrombocytosis becomes a life-threatening condition by causing severe complications such as hemorrhage and thrombosis development. Treatment is not recommended in patients who are asymptomatic and with a platelet count below 1,500,000/mm3, however, treatment is required in cases who are symptomatic and with a platelet count above 1,500,000/mm3 in conditions such as primary thrombocytosis. This article present the outcomes of a patient who was treated using low-dose hydroxyurea when he developed severe thrombocytosis after splenectomy.

1 January 2016 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
HSHakan Sarbay
Hakan Sarbay
Adenovirus is an infectious viral agent that causes variety of clinical presentations such as respiratory disease, conjunctivitis, and gastroenteritis. Hepatitis, pancreatitis, myocarditis, encephalitis, and disseminated infection are primarily seen in immunocompromised patients. Rarely, adenovirus infection can present with pertussis-like syndrome. Described here is case of pertussis-like syndrome associated with adenovirus presenting with hyperleukocytosis.

1 January 2018 in Pan African Medical Journal
Verified
Journal Article
Open access
HSHakan Sarbay
Hakan Sarbay
YAYılmaz Ay
Yılmaz Ay
INTRODUCTION: In this study, it is aimed to emphasize the causes and importance of macrocytosis in paediatric practice. METHODS: in the paediatric hematology and oncology clinic, 1752 patients evaluated in 2017, patients with macrocytosis were examined retrospectively with clinical and laboratory findings. Patients with macrocytosis were compared with the frequency of severe hematologic diseases such as acute leukemia and bone marrow failure in patients with normocytic and microcytic mean corpusculer volume. RESULTS: Macrocytosis was detected in 72 out of 1752 patients (4.1%) in the study. Acute lymphoblastic leukemia in 11(15.2%), acute myeloid leukemia in 3(4.1%), Fanconi aplastic anemia in 7(9.7%), Diamond-Blackfan anemia in 2(2.7%), aplastic anemia in 1(1.3%), congenital diseritropoetic anemia in 1(1.3%), deficiency of vitamin B12 in 14(19.4%) were diagnosed. Down syndrome was presented in 33 cases (45.8%). The number of patients with acute leukemia diagnosis was 14(0.8%) in the group in which the mean corpusculer volume was either microcytic or normocytic. The incidence of acute leukemia and bone marrow failure was significantly higher in the group with macrocytosis compared between the two groups. CONCLUSION: Although vitamin B12 deficiency is considered firstly in patients who have undergone cytopenia and macrocytosis in our country, haematological malignancies, bone marrow failures, myelodysplasia and myeloproliferative diseases should be remembered especially in the individuals with Down syndrome at the same time.